SAN FRANCISCO and GENEVA, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and orphan ophthalmological disorders, is pleased to announce the approval of all matters put forth to a vote of the shareholders at the company's Annual Shareholders Meeting.

The company presented seven resolutions to a vote of the shareholders and all were approved as follows:

1. To elect the five director nominees named in the Proxy Statement to hold office until the next annual meeting of stockholders;
2. To ratify the appointment of Marcum LLP as the Company's independent auditors for the fiscal year ending December 31, 2014;
3. To conduct an advisory vote on executive compensation;
4. To conduct an advisory vote on the frequency of future advisory votes on executive compensation;
5. To approve an amendment to the Company's Articles of Incorporation to increase the Company's authorized shares of common stock from 1,000,000,000 to 2,000,000,000;
6. To approve an amendment to the Company's First Amended 2008 Stock Plan to increase the number of shares of common stock authorized for issuance thereunder from 28,242,127 to 46,119,832;
7. To approve the Company's 2014 Stock Plan.

"The results of this shareholder vote clearly demonstrate that management and the Board of Directors have strong support from the company's shareholders to implement the mandate voted upon," said Gerald E. Commissiong, President & CEO of Amarantus. "Our goal is to up list Amarantus to a national exchange in the near-term and this positively positions the company to execute on this strategy in the months ahead."

The voting results may be found in the company's Form 8-K

About Amarantus Bioscience Holdings, Inc.

Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for orphan ophthalmological  disorders and other indications. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located in offices and labs at Janssen Labs @QB3. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

CONTACT: Amarantus Bioscience Holdings, Inc.
         Aimee Boutcher, Investor Relations
         408.737.2734 x 101
         ir@amarantus.com
         
         Planet Communications
         Deanne Eagle, Media Contact
         (917) 837-5866